RA0252

antibody from Oursmab

Targeting: FGFR2 BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0252

Provider

Oursmab

Product name

Bemarituzumab (Biosimilar Reference Antibody) (FGFR2)

Antibody type

Monoclonal

Description

Bemarituzumab (formerly FPA144) is a humanized monoclonal antibody of the IgG1 kappa isotype. It is an anticancer therapeutic designed with a dual mechanism of action. First, it functions as a signaling antagonist by binding to its target, thereby inhibiting the downstream tumor proliferation and survival pathways, such as MAPK and PI3K/AKT. Second, it is Fc-engineered (defucosylated) to enhance its affinity for the Fc gamma RIIIa (CD16a) receptor on Natural Killer (NK) cells, thereby boosting its Antibody-Dependent Cellular Cytotoxicity (ADCC) to directly destroy tumor cells. Bemarituzumab is primarily being investigated for the treatment of FGFR2b positive, unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.